$PIRS
Pieris Pharmaceuticals Inc Stock $pirs

$pirs Overview Financials Valuation SEC Filings Company Website

2018 Q3 Form 10-Q Financial Statement

#000158364818000049 Filed on August 09, 2018

Income Statement

Concept	2018 Q3	2018 Q2	2017 Q2
Revenue	$8.345M	$11.69M	$1.853M
YoY Change	112.5%	530.92%	72.72%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.750M	$4.780M	$4.350M
YoY Change	66.67%	9.89%	83.54%
% of Gross Profit
Research & Development	$11.40M	$9.155M	$5.396M
YoY Change	82.15%	69.66%	19.91%
% of Gross Profit
Depreciation & Amortization	$130.0K	$150.0K	$110.0K
YoY Change	116.67%	36.36%	-1200.0%
% of Gross Profit
Operating Expenses	$16.15M	$13.93M	$9.744M
YoY Change	77.25%	43.0%	41.87%
Operating Profit	-$7.804M	-$2.243M	-$7.891M
YoY Change	50.54%	-71.58%	36.16%
Interest Expense	$504.0K	$662.0K	$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$1.147M	$1.230M	-$1.380M
YoY Change	-166.34%	-189.13%	1471.74%
Pretax Income	-$6.153M	-$351.0K	-$9.271M
YoY Change	-10.99%	-96.21%	57.58%
Income Tax	$0.00	-$148.0K	$814.0K
% Of Pretax Income
Net Earnings	-$6.153M	-$203.0K	-$10.09M
YoY Change	-12.83%	-97.99%	71.42%
Net Earnings / Revenue	-73.73%	-1.74%	-544.25%
Basic Earnings Per Share
Diluted Earnings Per Share	-$113.7K	-$3.705K	-$232.2K
COMMON SHARES
Basic Shares Outstanding	54.03M shares	53.97M shares	43.07M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2018 Q3	2018 Q2	2017 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$137.3M	$151.0M	$50.30M
YoY Change	52.73%	200.2%	24.5%
Cash & Equivalents	$89.48M	$50.58M	$50.32M
Short-Term Investments	$47.80M	$100.4M
Other Short-Term Assets	$4.200M	$3.100M	$3.900M
YoY Change	50.0%	-20.51%	11.43%
Inventory
Prepaid Expenses
Receivables	$5.338M	$2.559M	$48.47M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$146.8M	$156.6M	$102.7M
YoY Change	54.13%	52.42%	134.14%
LONG-TERM ASSETS
Property, Plant & Equipment	$4.687M	$4.597M	$3.085M
YoY Change	35.64%	49.01%	26.08%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$0.00	$700.0K
YoY Change
Other Assets	$121.0K	$129.0K	$128.2K
YoY Change	-6.4%	0.62%	0.69%
Total Long-Term Assets	$4.808M	$5.426M	$3.213M
YoY Change	34.12%	68.86%	24.82%
TOTAL ASSETS
Total Short-Term Assets	$146.8M	$156.6M	$102.7M
Total Long-Term Assets	$4.808M	$5.426M	$3.213M
Total Assets	$151.7M	$162.0M	$106.0M
YoY Change	53.4%	52.92%	128.09%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.693M	$3.174M	$4.646M
YoY Change	3.51%	-31.69%	190.39%
Accrued Expenses	$5.981M	$4.562M	$6.351M
YoY Change	17.28%	-28.17%	173.11%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$40.59M	$52.33M	$35.80M
YoY Change	3.99%	46.2%	457.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$32.00K	$37.00K	$42.86K
YoY Change	-26.37%	-13.68%	1.9%
Total Long-Term Liabilities	$32.00K	$37.00K	$42.86K
YoY Change	-26.37%	-13.68%	1.9%
TOTAL LIABILITIES
Total Short-Term Liabilities	$40.59M	$52.33M	$35.80M
Total Long-Term Liabilities	$32.00K	$37.00K	$42.86K
Total Liabilities	$101.4M	$106.7M	$96.62M
YoY Change	7.52%	10.44%	954.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$135.4M	-$129.2M	-$120.7M
YoY Change	5.93%	7.03%	34.29%
Common Stock	$188.7M	$187.1M	$132.2M
YoY Change	39.93%	41.58%	2.83%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$50.26M	$55.32M	$9.334M
YoY Change
Total Liabilities & Shareholders Equity	$151.7M	$162.0M	$106.0M
YoY Change	53.4%	52.92%	128.09%

Cashflow Statement

Concept	2018 Q3	2018 Q2	2017 Q2
OPERATING ACTIVITIES
Net Income	-$6.153M	-$203.0K	-$10.09M
YoY Change	-12.83%	-97.99%	71.42%
Depreciation, Depletion And Amortization	$130.0K	$150.0K	$110.0K
YoY Change	116.67%	36.36%	-1200.0%
Cash From Operating Activities	-$14.36M	-$8.990M	-$6.520M
YoY Change	-140.8%	37.88%	6.71%
INVESTING ACTIVITIES
Capital Expenditures	-$320.0K	-$400.0K	-$670.0K
YoY Change	10.34%	-40.3%	1240.0%
Acquisitions
YoY Change
Other Investing Activities	$53.72M	-$48.37M	$10.00K
YoY Change		-483800.0%
Cash From Investing Activities	$53.40M	-$48.77M	-$660.0K
YoY Change	-18513.79%	7289.39%	1220.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	270.0K	70.00K	1.460M
YoY Change	-86.7%	-95.21%	-90.45%
NET CHANGE
Cash From Operating Activities	-14.36M	-8.990M	-6.520M
Cash From Investing Activities	53.40M	-48.77M	-660.0K
Cash From Financing Activities	270.0K	70.00K	1.460M
Net Change In Cash	39.31M	-57.69M	-5.720M
YoY Change	6.42%	908.57%	-162.72%
FREE CASH FLOW
Cash From Operating Activities	-$14.36M	-$8.990M	-$6.520M
Capital Expenditures	-$320.0K	-$400.0K	-$670.0K
Free Cash Flow	-$14.04M	-$8.590M	-$5.850M
YoY Change	-139.56%	46.84%	-3.47%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-06-30
	dei	Document Type DocumentType	10-Q
CY2017Q4	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	791000	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001583648
CY2018Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	54034689	shares
CY2018Q2	pirs	Accrued Research And Development Costs AccruedResearchAndDevelopmentCosts	124000	USD
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	PIERIS PHARMACEUTICALS, INC.
	dei	Trading Symbol TradingSymbol	PIRS
CY2018Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3174000	USD
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6170000	USD
CY2018Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4562000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15546000	USD
CY2018Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2559000	USD
CY2017Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1322000	USD
CY2018Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	898000	USD
CY2018Q2	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	102014000	USD
CY2018Q2	pirs	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	100000	USD
	pirs	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	-100000	USD
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	19000	USD
	pirs	Property And Equipment Included In Accounts Payable PropertyAndEquipmentIncludedInAccountsPayable	202000	USD
CY2017	pirs	Tax Cuts And Jobs Act Of2017 Incomplete Accounting Change In Tax Rate Income Tax Expense Benefit Before Valuation Allowance Impact TaxCutsAndJobsActOf2017IncompleteAccountingChangeInTaxRateIncomeTaxExpenseBenefitBeforeValuationAllowanceImpact	-3700000	USD
CY2017Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	6170000	USD
CY2018Q2	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4562000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2452000	USD
CY2017Q4	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	424000	USD
CY2018Q2	pirs	Accrued Tax Audit And Legal Fees AccruedTaxAuditAndLegalFees	253000	USD
CY2018Q2	pirs	Cash Cash Equivalents And Investments CashCashEquivalentsAndInvestments	151700000	USD
CY2017Q4	pirs	Cash Equivalents And Investments CashEquivalentsAndInvestments	62851000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2879000	USD
CY2018Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	3189000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-4695000	USD
CY2018Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-2574000	USD
CY2017Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	136484000	USD
CY2018Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	187067000	USD
CY2017Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3600000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	14700000	shares
CY2017Q4	us-gaap	Assets Assets	103876000	USD
CY2018Q2	us-gaap	Assets Assets	162025000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	89790000	USD
CY2018Q2	us-gaap	Assets Current AssetsCurrent	156599000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	982000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	199000	USD
CY2018Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	100316000	USD
CY2018Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	101099000	USD
CY2017Q2	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	29356000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50324000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37878000	USD
CY2018Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	50576000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	20968000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	12698000	USD
CY2017Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	44598000	USD
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	37153000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6796000	USD
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2018Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	45017062	shares
CY2018Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	54008056	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	45017062	shares
CY2018Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	54008056	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	45000	USD
CY2018Q2	us-gaap	Common Stock Value CommonStockValue	54000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10727000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-18670000	USD
CY2018Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3196000	USD
CY2017Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	46542000	USD
CY2018Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	54336000	USD
	us-gaap	Depreciation Depreciation	213000	USD
	us-gaap	Depreciation Depreciation	275000	USD
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	0.00
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	1096000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations	-825000	USD
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2325000	USD
CY2018Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1508000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4348000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8337000	USD
CY2018Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4779000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9131000	USD
CY2017Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9271000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17265000	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-351000	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9065000	USD
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	814000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	814000	USD
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-148000	USD
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-148000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-35780000	USD
	us-gaap	Increase Decrease In Operating Capital IncreaseDecreaseInOperatingCapital	-28584000	USD
CY2017Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	0	USD
CY2018Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	662000	USD
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	987000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	92354000	USD
CY2018Q2	us-gaap	Liabilities Liabilities	106707000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	103876000	USD
CY2018Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	162025000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	45775000	USD
CY2018Q2	us-gaap	Liabilities Current LiabilitiesCurrent	52334000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	22351000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-10085000	USD
CY2017Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	1507000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	2516000	USD
CY2018Q2	us-gaap	License And Services Revenue LicenseAndServicesRevenue	11224000	USD
	us-gaap	License And Services Revenue LicenseAndServicesRevenue	14668000	USD
CY2017Q4	us-gaap	Long Term Investments LongTermInvestments	9922000	USD
CY2018Q2	us-gaap	Long Term Investments LongTermInvestments	700000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1465000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	48228000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-842000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-57056000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	19249000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-18079000	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-203000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-8917000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	9744000	USD
	us-gaap	Operating Expenses OperatingExpenses	19093000	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	13934000	USD
	us-gaap	Operating Expenses OperatingExpenses	26222000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-7891000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-15897000	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-2243000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10379000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1308000	USD
CY2018Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1779000	USD
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	130000	USD
CY2018Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	129000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-642000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-591000	USD
CY2018Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	1266000	USD
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	519000	USD
CY2017Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	USD
CY2018Q2	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	2133000	USD
	us-gaap	Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	1602000	USD
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37000	USD
CY2018Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	37000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-23000	USD
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-54000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1380000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1368000	USD
CY2018Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	1230000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	327000	USD
CY2017Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
CY2018Q2	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	0	USD
	us-gaap	Other Sales Revenue Net OtherSalesRevenueNet	91000	USD
CY2018Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	400000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	808000	USD
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	67222000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	842000	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	0	USD
	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	10974000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	178000	USD
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001000
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2018Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	4963	shares
CY2018Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2907	shares
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	4963	shares
CY2018Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	2907	shares
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2018Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1615000	USD
CY2018Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3065000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	47207000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	839000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1287000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	182000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	6913000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	7786000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4034000	USD
CY2018Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4597000	USD
CY2017Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	346000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	680000	USD
CY2018Q2	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	467000	USD
	us-gaap	Research And Development Arrangement Contract To Perform For Others Compensation Earned ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned	1084000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5396000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10756000	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9155000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17091000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-120312000	USD
CY2018Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-129229000	USD
CY2017Q2	us-gaap	Revenues Revenues	1853000	USD
	us-gaap	Revenues Revenues	3196000	USD
CY2018Q2	us-gaap	Revenues Revenues	11691000	USD
	us-gaap	Revenues Revenues	15843000	USD
CY2018Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	8.00
	us-gaap	Share Based Compensation ShareBasedCompensation	1312000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2355000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	34751000	USD
CY2018Q2	us-gaap	Short Term Investments ShortTermInvestments	100399000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	11522000	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	55318000	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	1667000	USD
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43408000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43237000	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	53983000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	52025000	shares
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no financial instruments with off‑balance sheet risk such as foreign exchange contracts, option contracts, or other foreign hedging arrangements. Financial instruments that subject Pieris to concentrations of credit risk include cash and cash equivalents, investments, and accounts receivable. The Company’s cash, cash equivalents, and investments are held in accounts with financial institutions that management believes are creditworthy. The Company’s investment policy includes guidelines on the quality of the institutions and financial instruments, and defines allowable investments that the Company believes minimizes the exposure to concentration of credit risk. These amounts, at times, may exceed federally insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. Accounts receivable primarily consist of amounts due under strategic partnership and other license agreements with major multi-national pharmaceutical companies for which the Company does not obtain collateral.</font></div><div style="line-height:120%;padding-top:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"></font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:8px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of the financial statements in accordance with U.S. GAAP requires management to make estimates, judgments, and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses and the related disclosures at the date of the financial statements and during the reporting period. Significant estimates are used for, but are not limited to, revenue recognition; deferred tax assets, deferred tax liabilities and valuation allowances; fair value of stock options and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management’s estimates, judgments, and assumptions.</font></div></div>

Files In Submission

Name	View Source	Status
0001583648-18-000049-index-headers.html	Edgar Link	pending
0001583648-18-000049-index.html	Edgar Link	pending
0001583648-18-000049.txt	Edgar Link	pending
0001583648-18-000049-xbrl.zip	Edgar Link	pending
exhibit311q2.htm	Edgar Link	pending
exhibit312q2.htm	Edgar Link	pending
exhibit321q2.htm	Edgar Link	pending
exhibit322q2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
pirs-20180630.xml	Edgar Link	completed
pirs-20180630.xsd	Edgar Link	pending
pirs-20180630_cal.xml	Edgar Link	unprocessable
pirs-20180630_def.xml	Edgar Link	unprocessable
pirs-20180630_lab.xml	Edgar Link	unprocessable
pirs-20180630_pre.xml	Edgar Link	unprocessable
pirs6-30x201810xq.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PIRS
Pieris Pharmaceuticals Inc Stock $pirs

2018 Q3 Form 10-Q Financial Statement

#000158364818000049 Filed on August 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS Pieris Pharmaceuticals Inc Stock $pirs

2018 Q3 Form 10-Q Financial Statement

#000158364818000049 Filed on August 09, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PIRS
Pieris Pharmaceuticals Inc Stock $pirs